BR112014011262A2 - carboxamida com base em pirazolila substituída e derivados de ureia que portam uma porção de fenila substituída com um grupo contendo o como ligantes de receptor vaniloide - Google Patents
carboxamida com base em pirazolila substituída e derivados de ureia que portam uma porção de fenila substituída com um grupo contendo o como ligantes de receptor vaniloideInfo
- Publication number
- BR112014011262A2 BR112014011262A2 BR112014011262A BR112014011262A BR112014011262A2 BR 112014011262 A2 BR112014011262 A2 BR 112014011262A2 BR 112014011262 A BR112014011262 A BR 112014011262A BR 112014011262 A BR112014011262 A BR 112014011262A BR 112014011262 A2 BR112014011262 A2 BR 112014011262A2
- Authority
- BR
- Brazil
- Prior art keywords
- substituted
- group containing
- phenyl moiety
- urea derivatives
- vanyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Anesthesiology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Biotechnology (AREA)
Abstract
resumo patente de invenção: "carboxamida com base em pirazolila substituída e derivados de ureia que portam uma porção de fenila substituída com um grupo contendo o como ligantes de receptor vaniloide". a presente invenção refere-se a carboxamida com base em pirazolila substituída e derivados de ureia que portam uma porção de fenila substituída com um grupo contendo o como ligantes de receptor vaniloide, a composições farmacêuticas contendo esses compostos e também a esses compostos para o uso no tratamento e/ou profilaxia de dor e outras doenças e/ou desordens.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11008914.1 | 2011-11-09 | ||
EP11008914 | 2011-11-09 | ||
PCT/EP2012/072140 WO2013068461A1 (en) | 2011-11-09 | 2012-11-08 | Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an o-containing group as vanilloid receptor ligands |
Publications (3)
Publication Number | Publication Date |
---|---|
BR112014011262A2 true BR112014011262A2 (pt) | 2017-04-25 |
BR112014011262A8 BR112014011262A8 (pt) | 2018-03-06 |
BR112014011262B1 BR112014011262B1 (pt) | 2022-02-15 |
Family
ID=47143122
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014011262-2A BR112014011262B1 (pt) | 2011-11-09 | 2012-11-08 | Carboxamidas à base de pirazolila substituída e derivados de ureia, seu uso, e composição farmacêutica |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP2776398B1 (pt) |
JP (1) | JP6189313B2 (pt) |
KR (1) | KR101985442B1 (pt) |
CN (2) | CN103889961A (pt) |
AR (1) | AR088702A1 (pt) |
AU (1) | AU2012334065B2 (pt) |
BR (1) | BR112014011262B1 (pt) |
CA (1) | CA2854932A1 (pt) |
ES (1) | ES2823577T3 (pt) |
HK (1) | HK1201839A1 (pt) |
IN (1) | IN2014KN00849A (pt) |
MX (1) | MX2014005610A (pt) |
TW (1) | TW201326133A (pt) |
WO (1) | WO2013068461A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016096140A1 (en) * | 2014-12-19 | 2016-06-23 | Grünenthal GmbH | Process for the preparation of 1-[(heteroaryl)-methyl]- or 1-[(aryl)-methyl]-3-[4-(hydroxymethyl)-phenyl]-ureas |
WO2017170884A1 (ja) * | 2016-03-31 | 2017-10-05 | 富山化学工業株式会社 | 新規なヒドロキサム酸誘導体の製造方法およびその中間体 |
CN113135856B (zh) * | 2021-04-08 | 2022-10-11 | 天津大学 | 一类3-三氟甲基-5-氰基吡唑化合物及其制备方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999012910A1 (fr) * | 1997-09-11 | 1999-03-18 | Nissan Chemical Industries, Ltd. | Composes a base de pyrazole et agent de lutte contre les maladies vegetales |
WO2005048953A2 (en) * | 2003-11-13 | 2005-06-02 | Ambit Biosciences Corporation | Amide derivatives as kinase modulators |
JP2005314407A (ja) * | 2004-03-31 | 2005-11-10 | Nippon Nohyaku Co Ltd | 新規なハロアルキルスルホンアニリド誘導体、除草剤及びその使用方法並びにその中間体 |
PT1940821E (pt) * | 2005-10-19 | 2013-05-29 | Gruenenthal Gmbh | Novos ligandos do receptor de vanilóide e seu uso para a produção de medicamentos |
CN101679297B (zh) * | 2006-12-08 | 2012-01-11 | 埃克塞利希斯股份有限公司 | Lxr和fxr调节剂 |
DE102007018151A1 (de) * | 2007-04-16 | 2008-10-23 | Günenthal GmbH | Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln |
CA2758289A1 (en) * | 2009-05-07 | 2010-11-11 | Gruenenthal Gmbh | Substituted aromatic carboxamide and urea derivatives as vanilloid receptor ligands |
ES2640257T3 (es) * | 2009-05-07 | 2017-11-02 | Medifron Dbt Inc. | Fenilureas y fenilamidas sustituidas como ligandos del receptor vanilloide |
WO2011109441A1 (en) * | 2010-03-01 | 2011-09-09 | Myrexis, Inc. | Compounds and therapeutic uses thereof |
-
2012
- 2012-11-08 TW TW101141480A patent/TW201326133A/zh unknown
- 2012-11-08 CA CA2854932A patent/CA2854932A1/en not_active Abandoned
- 2012-11-08 MX MX2014005610A patent/MX2014005610A/es not_active Application Discontinuation
- 2012-11-08 ES ES12781340T patent/ES2823577T3/es active Active
- 2012-11-08 EP EP12781340.0A patent/EP2776398B1/en active Active
- 2012-11-08 AR ARP120104204A patent/AR088702A1/es unknown
- 2012-11-08 CN CN201280053470.3A patent/CN103889961A/zh active Pending
- 2012-11-08 CN CN201710970447.5A patent/CN107739338A/zh active Pending
- 2012-11-08 WO PCT/EP2012/072140 patent/WO2013068461A1/en active Application Filing
- 2012-11-08 BR BR112014011262-2A patent/BR112014011262B1/pt active IP Right Grant
- 2012-11-08 IN IN849KON2014 patent/IN2014KN00849A/en unknown
- 2012-11-08 KR KR1020147015424A patent/KR101985442B1/ko active IP Right Grant
- 2012-11-08 AU AU2012334065A patent/AU2012334065B2/en active Active
- 2012-11-08 JP JP2014540453A patent/JP6189313B2/ja active Active
-
2015
- 2015-03-12 HK HK15102528.0A patent/HK1201839A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
BR112014011262A8 (pt) | 2018-03-06 |
WO2013068461A1 (en) | 2013-05-16 |
CN103889961A (zh) | 2014-06-25 |
KR101985442B1 (ko) | 2019-06-03 |
EP2776398A1 (en) | 2014-09-17 |
HK1201839A1 (en) | 2015-09-11 |
TW201326133A (zh) | 2013-07-01 |
BR112014011262B1 (pt) | 2022-02-15 |
JP6189313B2 (ja) | 2017-08-30 |
ES2823577T3 (es) | 2021-05-07 |
JP2014532741A (ja) | 2014-12-08 |
KR20140091043A (ko) | 2014-07-18 |
AU2012334065A1 (en) | 2014-05-22 |
AU2012334065B2 (en) | 2017-06-08 |
IN2014KN00849A (pt) | 2015-10-02 |
CA2854932A1 (en) | 2013-05-16 |
CN107739338A (zh) | 2018-02-27 |
AR088702A1 (es) | 2014-06-25 |
MX2014005610A (es) | 2014-07-30 |
EP2776398B1 (en) | 2020-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014001880A2 (pt) | derivados de carboxamida e ureia contendo pirazol heteroaromáticos substituídos como ligantes de receptor vaniloide | |
BR112014001908A2 (pt) | derivados aza heterocíclicos substituídos | |
EA201591727A1 (ru) | Соединения биариламида в качестве ингибиторов киназы | |
BR112015003188A2 (pt) | Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
BR112015000578A2 (pt) | moduladores da via do complemento e usos dos mesmos | |
BR112013027670A2 (pt) | "composto de amida, composição farmacêutica e medicamento que o compreende e antagonista de rory" | |
EA200970967A1 (ru) | Оксадиазол замещенные производные индазола для применения в качестве агонистов сфингозин 1-фосфата (sip) | |
BR112015029090A8 (pt) | 3,4-dihidroisoquinolin- 2(1h)-ila, seus usos, composição farmacêuticas e sua forma cocristalina | |
BR112015016395A2 (pt) | pirazóis 3-substituídos e uso como inibidores de dlk | |
EA201070327A1 (ru) | Катехоламиновые производные и их пролекарства | |
EA201370166A1 (ru) | Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы | |
UA109290C2 (uk) | Спільні кристали і солі інгібіторів ccr3 | |
EA201201658A1 (ru) | Производные пиперидина и их применение для лечения метаболических нарушений | |
BR112013026807A2 (pt) | derivados de metil amina bicíclicos substituídos como moduladores dos receptores de esfinfgosina-1 fosfato | |
EA201590562A1 (ru) | Бензамиды | |
BR112014012459A2 (pt) | 2h-indazóis como antagonistas do receptor de ep2 | |
BR112014005025A2 (pt) | composição farmacêutica para uso no tratamento de uma doença neurodegenerativa | |
CY1116234T1 (el) | Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3 | |
UY33568A (es) | Compuestos que interactuan con proteina reguladora de glucocinasa para el tratamiento de diabetes. | |
CY1116158T1 (el) | Υποκατεστημενα 2-οξο- και 2-θειοξο-διυδροκινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3 | |
BR112014001714A2 (pt) | derivados de carboxamida e ureia aromáticos bicíclicos substituídos como ligantes de receptor vaniloide | |
BR112014006675A2 (pt) | derivados de metanossulfonamida substituídos como ligantes de receptor vaniloide | |
BR112014011262A2 (pt) | carboxamida com base em pirazolila substituída e derivados de ureia que portam uma porção de fenila substituída com um grupo contendo o como ligantes de receptor vaniloide | |
BR112014006788A2 (pt) | derivados de metanossulfonamida substituídos com arila ou n-heteroarila como ligantes de receptor vaniloide | |
BR112014011108A2 (pt) | derivados de carboxamida e ureia à base de pirazolila substituída portando uma porção fenila substituída com um grupo contendo so2 como ligantes do receptor de vaniloides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: MEDIFRON DBT INC. (KR) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/11/2012, OBSERVADAS AS CONDICOES LEGAIS. |